(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
Edwards Lifesciences Secures CE Mark for Sapien M3 Mitral Valve Replacement System
Edwards Lifesciences has received the CE mark for its Sapien M3 transcatheter mitral valve replacement system, marking a significant milestone in its transcatheter mitral and tricuspid therapies (TMTT) strategy. The system, designed for patients with symptomatic mitral regurgitation who are not suitable for surgery or edge-to-edge repair, is the first globally to use a transfemoral approach for this condition.
The approval enables Edwards to offer a full portfolio in the EU for mitral and tricuspid valve repair and replacement, joining its Pascal and Evoque systems. Sapien M3 now enters a competitive European market already served by Abbott’s MitraClip and Edwards’ own Pascal repair device.
Edwards is aiming for FDA approval of Sapien M3 by 2025 and expects its TMTT portfolio to grow significantly, with projected sales reaching $2 billion by 2030.
23-04-2025
📰 Recent News
- Medtronic Seeks FDA Approval for Hugo Surgical Robot, Aiming to Challenge Intuitive
- FDA Warns ICU Medical Over Unapproved Changes to Infusion Pumps
- Medtronic Gains FDA Approval for World’s Smallest Defibrillation Lead, Omniasecure
- Abbott Links Glucose Monitoring Data with Epic’s Electronic Health Records
- Intuitive obtains new FDA nod for single port robot and Resmed buys diagnostic facility
- Ceribell wins FDA nod for algorithm to detect pediatric seizures
- Medtronic obtains FDA approval to utilise Simplera Sync glucose sensor integrated with insulin pumps
- Precision Neuroscience receives FDA clearance for brain implant
- FDA issues early alert for BD catheters due to leaks
- Medtronic seeks FDA approval for insulin pump, furthering Abbott collab